ML-792 impairs Trypanosoma brucei growth through SUMO pathway disruption: toward E1 as a candidate antitrypanosomal target
Frontiers in Cellular and Infection Microbiology · 19.06.2026 · 16
DOI: 10.3389/fcimb.2026.1850640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 19.06.2026. Verfasst von Emily Denise Fischman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM) - Consejo Nacional de Investigaciones Científicas y Técnicas…. Hauptthemen laut MEDLINE: Trypanosoma brucei brucei, Sumoylation, Small Ubiquitin-Related Modifier Proteins, Ubiquitin-Activating Enzymes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
African trypanosomiasis is a neglected disease affecting humans and animals in sub-Saharan Africa, caused by extracellular parasites of the Trypanosoma brucei species complex. Despite recent progress in disease control, current treatments are limited by toxicity, emerging resistance, and incomplete understanding of their mechanisms of action, highlighting the need for new targeted therapeutic strategies. In Trypanosoma brucei , post-translational modifications such as SUMOylation play essential roles in cellular processes, including cell cycle progression and variable surface antigen expression, making this pathway an attractive therapeutic target. We evaluated the effect of ML-792, a selective inhibitor of the SUMO-activating enzyme (E1, SAE), on bloodstream form parasites. Structural analysis showed conservation of key features of the E1 enzyme, consistent with susceptibility to inhibition. ML-792 treatment reduced global SUMO conjugation and nuclear SUMO levels and impaired parasite proliferation in a dose-dependent manner, with an IC 50 in the micromolar range, and induced defects in cell cycle progression, including abnormal nuclei/kinetoplast configurations. These results demonstrate that pharmacological inhibition of SUMOylation disrupts essential processes in T. brucei and support the SUMO pathway as a potential target for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), San Martin, Argentina.
- Escuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín, San Martin, Argentina.
Zitieren
APA
Fischman, E. D., Serassio, M., Alvarez, V. E., & Iribarren, P. A. (2026). ML-792 impairs Trypanosoma brucei growth through SUMO pathway disruption: toward E1 as a candidate antitrypanosomal target. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1850640
Vancouver
Fischman ED, Serassio M, Alvarez VE, Iribarren PA. ML-792 impairs Trypanosoma brucei growth through SUMO pathway disruption: toward E1 as a candidate antitrypanosomal target. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1850640
BibTeX
@article{Fischman2026,
author = {Fischman, Emily Denise and Serassio, Melina and Alvarez, Vanina Eder and Iribarren, Paula Ana},
title = {ML-792 impairs Trypanosoma brucei growth through SUMO pathway disruption: toward E1 as a candidate antitrypanosomal target},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1850640}
}
EUVIMED